cyrilzakka/clinical-trials huggingface dataset:
Canadian Aesthetic Experience With Sculptra Therapy

Primary objective To evaluate the degree of correction achievable with Sculptra for nasolabial folds, mid- and lower facial volume loss, jawline laxity and other signs of facial ageing.

To document the types and incidence of device-related adverse events with Sculptra.


Eligibility Criteria:
Inclusion Criteria:

* Present with nasolabial folds, mid- and lower facial volume loss, jawline laxity or other signs of facial ageing to be treated with Sculptra
* The subject must be willing and able to provide written informed consent that includes a release for use of their photographs in publications. Subjects who refuse the photo release will not be eligible to participate in the study.
* Female subjects must be post-menopausal for at least one year or have had a hysterectomy or tubal ligation; if of child-bearing potential, must agree to use an approved method of birth control throughout the study (i.e., oral/systemic contraceptives, intrauterine device (IUD), or spermicide in combination with a barrier method of contraception);

Exclusion Criteria:

* Personal history of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine);
* Known history of bleeding disorders;
* Active inflammatory process in the area to be treated (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, or any other active skin disease);
* Active hepatitis within the past year;
* Subjects who are pregnant or who plan to become pregnant within the study timeframe, or who are breastfeeding;
* HIV positive patients;
* Recent history of trauma in the face (\< 1 year);
* Previous use of Dermalive or Dermadeep;
* Previous facial surgery within the last six months;
* Recent facial filler within the last six months;
* Planned surgical interventions (such as rhinoplasty, facelift, congenital defect repair) or use of other fillers or lasers for the initial six months post-Sculptra therapy;
* Subjects with clinically important disease as judged by the investigator within 3 months of the start of the study (e.g., history of significant lab abnormalities, myocardial infarct, stroke, cancer, connective tissue disease, etc.), including subjects with medical conditions that might require the use of immunosuppressive medications during the trial (severe asthma, rheumatoid arthritis, organ transplant, etc.);
* Subjects who have used superficial dermal resurfacing procedures in the facial area, including chemical peel, dermabrasion, or microderm treatments within six weeks of visit 1 and for the duration of the main study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
2. Age≥18 years;
3. Staging TanyN3M0 (AJCC/UICC 9th edition) ;
4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
5. White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;
6. Transaminases≤2.5 times the upper limit of normal, total bilirubin \<1.5 times the upper limit of normal;
7. Creatinine clearance ≥60 ml/min;
8. Signed informed consent form.

Exclusion Criteria:

1. HBsAg positive and HBV DNA \>1×103 copy/ml;
2. Patients with positive HCV antibody test results;
3. Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
4. History of interstitial lung disease;
5. Received systemic sex hormone or other immunosuppressive therapy with equivalent dose \> 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
6. Have received or will receive live vaccine within 30 days before signing the informed consent;
7. Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
8. Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
9. The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
10. Human immunodeficiency virus (HIV) infection;
11. Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.
Effects of Neuromuscular Pelvic Realigning Exercises on Pelvic Floor Muscle Function in Continent SubjectS

The goal of this research study is to investigate the effect of a new neuromuscular approach for correcting pelvic alignment and improving pelvic floor muscle function. Investigators hypothesized that this approach would be significantly superior than no intervention to improve the ability of pelvic floor muscle contraction, measured by transabdominal sonography as bladder base elevation. Participants will be randomized to the intervention and control groups. while intervention group will receive five supervised sessions of pelvic realigning exercises, the control group will receive no intervention. Bladder base elevation will be measured as an indicator of pelvic floor muscle function, before and after one week intervention in both control and intervention groups.


Eligibility Criteria:
Inclusion Criteria:

Positive Ober's test

Exclusion Criteria:

* pelvic/low back pain in previous 12 months
Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery

This is a Randomized trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery. In this trial patients with left sided colon and rectal tumors were randomized to receive mechanical bowel preparation or no preparation to assess postoperative complications and outcome

In this prospective randomized trial,patients were randomized to receive mechanical bowel preparation or no preparation to assess postoperative complications and outcome following elective laparoscopic surgery for left sided colon and rectal tumors. Randomization is done from the out -patient department at the time of admission, using random numbers from a computer generated list from a sealed envelope method.

Patients who did not have mechanical bowel preparation had a normal meal on the day before the operation. Those who did were given a fluid diet, and mechanical bowel preparation with polyethylene glycol one day prior to surgery.

Both groups will have the scheduled laparoscopic colonic resections. Use of diverting stoma is left to the discretion of the operating surgeon. Cases that needed a diverting stoma, will be analyzed separately.

Eligibility Criteria:
Inclusion Criteria:

* left sided colonic and rectal tumors
* eligible for elective laparoscopic surgery

Exclusion Criteria:

* Patients with intestinal obstruction or perforation.
* patients with T4b tumors.
* metastatic tumors
* patients with multiple previous abdominal surgeries
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics. Past behavioral science interventions have shown promise in increasing flu vaccinations. For example, successful interventions have encouraged people to make concrete plans for when they will get a flu vaccination, sent automated calls or text messages reminding patients to get a flu vaccination , or provided financial incentives for getting vaccinated. Although these results are promising, these studies have been conducted in isolation on different populations, which makes it difficult to compare their interventions' effectiveness or to have enough power to reliably detect differing responses to interventions based on individual characteristics.

This research will simultaneously test 22 different SMS interventions to increase flu vaccinations compared to a holdout control condition in a "mega-study" and apply machine learning to identify which interventions work best for whom. The interventions are designed by behavioral science experts from the Behavior Change for Good Initiative (BCFG), Penn Medicine Nudge Unit (PMNU), and Geisinger Behavioral Insights Team (BIT). Customers of a large retail pharmacy who received a flu shot from the pharmacy last year and receive SMS notifications will be included in this study. We expect this to include approximately 1.2 million participants.

The specific aims of this research are to identify (1) which behavioral science strategies effectively increase flu vaccination rates overall, and (2) which strategies are most effective for different subgroups (e.g., based on age, gender, race).


Eligibility Criteria:
Inclusion Criteria:

1. Have agreed to receive SMS messages from the pharmacy
2. Received a flu shot from the pharmacy in the 2019-2020 flu season, as documented in their pharmacy records.

Exclusion Criteria:

-
Unilateral Biportal Endoscopy Lumbar Interbody Fusion (ULIF) Versus Posterior Lumbar Interbody Fusion (PLIF) in Management of Single Level Lumbar Degenerative Disease: A Retrospective Study

The study aimed to compare the clinical efficacy and safety of unilateral biportal endoscopic lumbar interbody fusion (ULIF) with posterior lumbar interbody fusion (PLIF) in the treatment of single-level lumbar degenerative diseases.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who have been diagnosed with lumbar disc herniation, lumbar spinal stenosis, or lumbar spondylolisthesis based on their medical history, physical signs, and imaging exams such as lumbar anteroposterior and lateral radiographs (including hyperextension and hyperflexion positions), lumbar CT, and lumbar MR. (2) The patient has clear indications for surgical treatment: ① Conservative treatment for more than three months has been ineffective or the symptoms have continued to worsen ② The patient's symptoms are severe and interfere with their daily work and life ③ The patient exhibits signs of cauda equina nerve compression (such as numbness in the perineal area, loss of bowel and bladder control, etc.).

(3) The patient is undergoing their initial single-segment ULIF or PLIF surgery at our hospital.

Exclusion Criteria:

1. Patients with lumbar degenerative diseases involving two or more segments
2. Pathological changes caused by other diseases, such as spinal infections, spinal trauma, spinal tumors, neurological diseases, etc.
3. Patients with lumbar spondylolisthesis exceeding Meyerding Grade II or degenerative scoliosis with a Cobb angle greater than 20 degrees
4. History of previous lumbar surgery
5. History of previous tumor disease.
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy subjects aged 15-19 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose.

The study is open. However, the 4 different formulations of GSK's MenACWY conjugate vaccine will be administered in a double-blind manner. Mencevax™ ACWY vaccine will serve as active control. Subjects will receive one vaccine dose only (GSK's MenACWY conjugate vaccine or Mencevax™ ACWY vaccine), and will have 2 blood samples taken, before and one month after vaccination.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female between, and including, 15 and 19 years of age at the time of vaccination.
* Subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge.
* Female subjects should be of non-childbearing potential.

Exclusion Criteria:

* Previous vaccination against OR history of OR exposure within previous 12 months to meningococcal serogroup A, C, W-135 or Y disease.
* Administration of a tetanus vaccine within 6 months before study vaccination.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
* A family history of congenital or hereditary immunodeficiency.
* History of any neurologic disorders or seizures.
PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes

This is a monocentric cohort study conducted in the cardiology department of Nancy hospital. The main purpose of the study is to document the global management strategy of patients hospitalized for heart failure and evaluate the association between patient's care and post-hospitalization outcome.


Eligibility Criteria:
Inclusion Criteria:

* Man or women ≥ 18 years
* Patients hospitalized for cardiac decompensation (ESC 2016 and 2021 criteria)

Exclusion Criteria:

* Patient expressing refusal to participate in research
* Patient who is a minor or under administrative protection
* Pregnant women
* Patient with ventricular assistance
* Patient with congenital heart disease
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

The aim of this trial is to explore the real-world patient-reported health-related quality of life (HRQOL), functioning, symptoms and symptom tolerability of sacituzumab govitecan or chemotherapy of the physician's choice for Chinese mTNBC patients. Evaluation of HRQOL and functioning using the EORTC QLQ-C30 and QLQ-BR45 questionnaires, including change from baseline and time to deterioration in each scale or item. Treatment-related symptoms and tolerability were assessed using the Patient-Reported Outcomes of the PRO-CTCAE and PGI-TT questionnaires.


Eligibility Criteria:
Inclusion Criteria:

1. Patients aged over 18 years old.
2. Patients have been diagnosed with metastatic triple-negative breast cancer (mTNBC). ER, PgR, and HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections. ER-negative and PgR-negative status was defined as≤1% staining in the nuclei by IHC. HER2-negative status was defined by IHC staining 0 to 1+ or fluorescence in situ hybridization ratio \<2.0 if IHC 2+ or IHC not performed.
3. The metastatic disease was confirmed by clinical, imaging, histological, or cytological measures, including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
4. Patients who have received at least 1 prior regimen in the metastatic setting.
5. Plan to receive or has received sacituzumab govitecan monotherapy or chemotherapy of the physician's choice.
6. Available medical history.
7. All patients can provide an informed consent before enrolment and data collection.

Exclusion Criteria:

1. If participating in any controlled clinical trial, the subject cannot take part in this study.
2. HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.
3. Pregnancy and lactation.
4. Severe hepatic impairment.
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.

This prospective, multi-center, single-arm feasibility study is planned to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate in patients presenting for treatment of prostate cancer. Study participants will have placement of the drug eluting Biolen and be followed through scheduled radical prostatectomy.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate.
* Study participant qualified and planning for radical prostatectomy.
* At least 1 prostate lesion measurable by MRI \> 0.5 cm within one month of screening.
* PSA \> 3 ng/mL within 3 months of screening.
* Gleason score 3+4 or higher.
* Study participant must be willing to undergo post-treatment imaging by MRI.
* ECOG performance status 0 or 1.

Exclusion Criteria:

* Prior radiotherapy or surgery for prostate cancer.
* Prior or ongoing hormonal therapy for prostate cancer.
* Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive BPH procedure.
* Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
* Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images.
* Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of \> 3 months.
* Presence of any metastatic disease.
* Prostate volume more than 80 cc at prior MRI imaging.
* I-PSS score \>20.
* History of prostate infection.
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome

The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of IBS according to Rome III criteria, additionally abdominal distension or flatulence the most disturbing symptom
* Age 18-65 years
* Colonoscopy conducted within the previous 5 years, finding macroscopically and histologically normal

Exclusion Criteria:

* Organic GI disease. Treated (min. 1 year) coeliac disease patients, and subjects with known and treated lactose intolerance are allowed to participate
* Malignancy
* Significant gastrointestinal surgery
* Clinically significant aberrancies in the screening-phase laboratory analyses
* Changes in regular medication during the previous 4 weeks
* Pregnancy or breast feeding
* Other disease or state that based on the investigator's evaluation complicates the conduction of the intervention, i.e. alcoholism, dementia
* Hereditary galactosemia
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss

High bone turnover with the bone resorption exceeding bone formation is a major mechanism of postmenopausal osteoporosis. Therefore, inhibition of bone resorption is a rational approach for the prevention. The Objective of the current study was to determine the short-term efficacy of once-weekly low dose alendronate in the prevention of bone loss in early postmenopausal Korean women with moderate bone loss via bone turnover markers.

This study was a 12-week, randomized, double-blind clinical trial compared the effects of placebo with alendronate 20 mg once weekly. All subjects received supplemental calcium 600 mg and vitamin D 400 IU daily. Fifty two postmenopausal women (the ages between 50-65 year) with lumbar spine BMD at least 2.0 SD below the peak young adult mean were recruited at Eulji University Hospital, Daejeon, Korea. BMD was measured by DXA at baseline and serum alkaline phosphatase, osteocalcin and C-terminal telopeptide of type I collagen was measured at baseline and 12 weeks after treatment.


Eligibility Criteria:
Inclusion Criteria:

* postmenopausal women (the ages between 50-65 year) with lumbar spine BMD at least 2.0 SD below the peak young adult mean

Exclusion Criteria:

* severe osteoporosis
* current medication of osteoposis
* metabolic bone disease
* cancer, stroke etc.
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.

Only patients with 0 to 1 performance status on the ECOG scale are eligible.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological).
* Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer.
* Measurable disease per RECIST criteria.
* Adequate bone marrow, hepatic and renal function.

Exclusion Criteria:

* Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years.
* Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days.
* Known hypersensitivity to minocycline.
* History of serious cardiac disease that is not controlled.
* Serious eye conditions.
* Prior treatment with inhibitors of EGFR of any kind.